List of Myfembree drug patents
Myfembree is owned by Myovant Sciences.
Myfembree contains Estradiol; Norethindrone Acetate; Relugolix.
Myfembree has a total of 4 drug patents out of which 0 drug patents have expired.
Myfembree was authorised for market use on 26 May, 2021.
Myfembree is available in tablet;oral dosage forms.
Myfembree can be used as management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Drug patent challenges can be filed against Myfembree from 2024-12-18.
The generics of Myfembree are possible to be released after 29 September, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(10 months from now) | |
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9346822 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(10 months from now) | |
| US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
| New Product (NP) | May 26, 2024 |
| New Indication (I) | Aug 5, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
MYFEMBREE family patents
20
United States
8
Japan
8
European Union
5
Australia
4
China
4
Canada
4
Israel
3
Brazil
3
New Zealand
3
Argentina
3
Mexico
3
Morocco
3
EA
2
Portugal
2
Spain
2
Norway
2
Lithuania
2
Slovenia
2
Hungary
2
Poland
2
Denmark
1
Moldova, Republic of
1
Russia
1
Croatia
1
Colombia
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
South Africa
1
Cyprus
1
RS
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic